3 Healthcare Stock Stories For Weekend Investment Wellness

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Vvus Inc. (NASDAQ:VVUS): Closing price $14.70

As it fights with its biggest investor for board control, Vivus told investors and analysts at a meeting on Friday that it is open to negotiating a potential resolution with its shareholder First Manhattan Co., according to two persons attending the event, who elaborated that Vivus would attempt to reach a settlement prior to its annual meeting on July 15.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

VVUS

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH): Closing price $0.5074

On Friday, Anthera reported that it has filed a certificate of amendment to its amended and restated certificate of incorporation to set up a 1-for-8 reverse stock split of its common stock, effective as of 5:00 p.m. Eastern time today. The certificate of amendment was approved by Anthera’s stockholders at its Annual Meeting of Stockholders held on May 16, and the specific 1-for-8 ratio was later approved by the board.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ANTH

Qiagen N.V. (NASDAQ:QGEN): Closing price $20.59

Qiagen announced Friday that it has received approval by the FDA to market the therascreen EGFR test as a companion diagnostic to guide the use of Boehringer Ingelheim’s new targeted therapy, Gilotrif (afatinib), to treat metastatic NSCLC in patients who have tumors with certain EGFR gene mutations. Over 200,000 new lung cancer cases are diagnosed yearly in the United States, with NSCLC comprising some 85 percent of cases, causing an estimated 160,000 deaths.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

QGEN

Don’t Miss: Will Medicaid Complexities Leave Many Still Uninsured?

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business